文献速递其他结缔组织病

英夫利西单抗治疗难治性多发性肌炎和皮肌炎的随机双盲安慰剂对照试验

A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.
PubMed 文献 · Semin Arthritis Rheum · 2017-10-16

一项随机双盲安慰剂对照先导试验纳入活动性多发性肌炎或皮肌炎患者,在第0、2、6、14周分别输注英夫利西单抗5mg/kg或安慰剂,主要终点为第16周徒手肌力较第0周改善≥15%。12例完成至第16周,英夫利西单抗5mg/kg组6例中仅1例达到应答标准;安慰剂组6例第16周后交叉至英夫利西单抗5mg/kg,其中2例应答。英夫利西单抗耐受性良好,可能使部分患者获益。

要点

  • 英夫利西单抗5mg/kg组6例中仅1例在第16周达到MMT改善≥15%的应答标准。
  • 安慰剂组6例第16周后交叉至英夫利西单抗5mg/kg,其中2例应答。
  • 英夫利西单抗治疗难治性多发性肌炎和皮肌炎耐受性良好,可能使部分患者获益。

核心结论

  • 英夫利西单抗治疗难治性多发性肌炎和皮肌炎耐受性良好,可能使部分患者获益。

研究设计与样本

  • 随机双盲安慰剂对照先导试验,纳入活动性皮肌炎或多发性肌炎患者,免疫抑制药物剂量稳定且泼尼松≤0.5mg/kg/天,入组前至少4周存在肌无力临床体征。
  • 受试者在第0、2、6、14周盲法输注安慰剂或英夫利西单抗5mg/kg,主要终点为第16周徒手肌力较第0周改善≥15%,次要终点为国际肌炎评估和临床研究组(IMACS)标准定义的改善。
  • 第16周时各臂应答者可选继续原治疗或换为该臂无应答者治疗,英夫利西单抗5mg/kg臂无应答者加量至7.5mg/kg于第22、30、38周给药,安慰剂臂无应答者于第16、18、22、30、38周接受英夫利西单抗5mg/kg,第40周重新评估结局。

主要发现

  • 12例受试者完成研究至第16周。
  • 英夫利西单抗5mg/kg臂6例中仅1例达到应答标准。
  • 英夫利西单抗臂其余5例中3例交叉至英夫利西单抗7.5mg/kg剂量,其中1例应答。
  • 安慰剂臂6例在第16周后全部交叉至英夫利西单抗5mg/kg方案,其中2例对英夫利西单抗应答。

关键数值与推荐

  • 主要终点为第16周徒手肌力较第0周改善≥15%。
  • 次要终点为国际肌炎评估和临床研究组(IMACS)标准定义的改善。
  • 英夫利西单抗给药方案为5mg/kg于第0、2、6、14周输注。
  • 英夫利西单抗5mg/kg臂无应答者加量至7.5mg/kg于第22、30、38周给药。
  • 安慰剂臂无应答者于第16、18、22、30、38周接受英夫利西单抗5mg/kg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate in a pilot study the safety and efficacy of infliximab in patients with refractory dermatomyositis (DM) and polymyositis (PM). METHODS: A randomized, double-blind, placebo-controlled trial including subjects with active DM or PM. Participants had stable doses of immunosuppressive medication and prednisone (≤0.5mg/kg/day), and exhibited clinical signs of muscle weakness for at least 4 weeks prior to study entry. Participants received infusions of either placebo or infliximab 5mg/kg at 0, 2, 6, and 14 weeks in blinded manner. The primary outcome was a ≥15% manual muscle strength (MMT) improvement at week 16 compared to week 0. The secondary outcome measures were improvement defined by the International Myositis Assessment and Clinical Studies Group (IMACS) criteria. At week 16, responders in each arm had the option of either continuing the same treatment or changing to the non-responder treatment for that study arm. Non-responders in the 5mg/kg infliximab arm were increased to infliximab 7.5mg/kg for weeks 22, 30, and 38. Non-responders in the placebo arm at week 16 received infliximab 5mg/kg at weeks 16, 18, 22, 30, and 38. Outcomes were reassessed at week 40. RESULTS: Twelve subjects completed the study to week 16. Six of the 12 subjects received infliximab treatment at the dose of 5mg/kg with only one subject meeting the responder criteria at that dose. Of the remaining five subjects on infliximab, three crossed over to the infliximab 7.5mg/kg dose. One of those three subjects responded. All six patients in the placebo arm crossed over to the 5mg/kg dosing regimen after week 16, and two of those responded to infliximab. CONCLUSIONS: Infliximab therapy for patients with refractory PM and DM was well tolerated and may benefit a subset of patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Schiffenbauer A, Garg M, Castro C, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2017. PMID: 29174792. doi:10.1016/j.semarthrit.2017.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。